Shah Jatin 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 19, 2020
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2020-02-15+4,850→ 42,134 total - Exercise/Conversion
Restricted Stock Units
2020-02-15−4,850→ 14,550 total→ Common Stock (4,850 underlying)
Footnotes (3)
- [F1]Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- [F2]Includes 2,659 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.
- [F3]On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.